A Clinical Trial Evaluating TQB2930 Injection and Chemotherapy With or Without Bevacizumab in Patients With HER2-Abnormally Expressed Unresectable Locally Advanced or Metastatic Colorectal Cancer.
A Phase Ib/II Clinical Study to Evaluate the Efficacy and Safety of TQB2930 Injection and Chemotherapy With or Without Bevacizumab in Participants With HER2-Abnormally Expressed Unresectable Locally Advanced or Metastatic Colorectal Cancer.
To assess the safety and preliminary efficacy of TQB2930 and chemotherapy with or without bevacizumab in sparticipants with HER2-Abnormally Expressed locally advanced or metastatic colorectal cancer (CRC).
研究概览
地位
条件
研究类型
注册 (估计的)
阶段
- 阶段2
- 阶段1
联系人和位置
学习联系方式
- 姓名:Ruihua Xu, Doctor
- 电话号码:020-87343468
- 邮箱:xurh@syscc.org.cn
学习地点
-
-
Beijing Municipality
-
Beijing、Beijing Municipality、中国、100034
- 尚未招聘
- Peking University First Hospital
-
接触:
- Shikai Wu, Doctor
- 电话号码:15810037307
- 邮箱:Skywu4923@sina.com
-
-
Chongqing Municipality
-
Chongqing、Chongqing Municipality、中国、400016
- 尚未招聘
- The First Affiliated Hospital of Chongqing Medical University
-
接触:
- Tao Zhang, Doctor
- 电话号码:13708311156
- 邮箱:tumorzzt@163.com
-
-
Gansu
-
Lanzhou、Gansu、中国、730050
- 尚未招聘
- Gansu Provincial Tumor Hospital
-
接触:
- Zhihu Li, Master
- 电话号码:18993042850
- 邮箱:245698692@qq.com
-
-
Guangdong
-
Foshan、Guangdong、中国、528000
- 尚未招聘
- The First People's Hospital of Foshan
-
接触:
- Wei Wang, Doctor
- 电话号码:18038863618
- 邮箱:wangwei@fsyyy.com
-
Guangzhou、Guangdong、中国、510060
- 招聘中
- Sun Yat-sen University Cancer Center
-
接触:
- Ruihua Xu, Doctor
- 电话号码:020-87343468
- 邮箱:xurh@syscc.org.cn
-
Guangzhou、Guangdong、中国、510000
- 尚未招聘
- The Sixth Affiliated Hospital, Sun Yat-sen University
-
接触:
- Yanhon Den, Doctor
- 电话号码:13925106525
- 邮箱:dengyanh@mail.sysu.edu.cn
-
-
Guangxi
-
Nanning、Guangxi、中国、530000
- 尚未招聘
- Guangxi Zhuang Autonomous Region Cancer Hospital
-
接触:
- Rong Liang, Doctor
- 电话号码:18677070811
- 邮箱:53371159@qq.com
-
-
Guizhou
-
Zunyi、Guizhou、中国、563000
- 招聘中
- The Affiliated Hospital of Zunyi Medical University
-
接触:
- Jiwei Wang, Doctor
- 电话号码:18013964231
- 邮箱:zmu_wangjw@163.com
-
-
Heilongjiang
-
Harbin、Heilongjiang、中国、150000
- 尚未招聘
- Harbin Medical University Cancer Hospital
-
接触:
- Tongsen Zheng, Doctor
- 电话号码:15134569619
- 邮箱:zhengtongsen@126.com
-
接触:
- Yuxian Bai, Doctor
- 电话号码:13945095085
- 邮箱:bai_yuxian@126.com
-
Qiqihar、Heilongjiang、中国、161005
- 尚未招聘
- Qiqihar First Hospital
-
接触:
- Xiyuan Sun, Doctor
- 电话号码:13945258792
- 邮箱:sunxiyuan2004@126.com
-
-
Henan
-
Zhengzhou、Henan、中国、450000
- 尚未招聘
- Henan Cancer Hospital
-
接触:
- Ying Liu, Doctor
- 电话号码:13783604602
- 邮箱:yaya7207@126.com
-
Zhengzhou、Henan、中国、450000
- 尚未招聘
- The Third People's Hospital of Zhengzhou
-
接触:
- HaiCun Wang, Master
- 电话号码:13803833783
- 邮箱:whc1975@126.com
-
Zhengzhou、Henan、中国、450000
- 尚未招聘
- The first affiliated hospital of Zhengzhou university
-
接触:
- Yongxu Jia, Doctor
- 电话号码:15237128281
- 邮箱:fccjiayx@zzu.edu.cn
-
-
Hubei
-
Jingzhou、Hubei、中国、434099
- 尚未招聘
- Jingzhou First People's Hospital
-
接触:
- Yan Hu, Master
- 电话号码:18163137369
- 邮箱:helensparkle@163.com
-
Wuhan、Hubei、中国、430022
- 尚未招聘
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
-
接触:
- Hongli Liu, Doctor
- 电话号码:13995680822
- 邮箱:hongliliu@hust.edu.cn
-
-
Hunan
-
Changsha、Hunan、中国、410013
- 招聘中
- Hunan Cancer Hospital
-
接触:
- Yi He, Doctor
- 电话号码:18692237222
- 邮箱:heyi@hnca.org.cn
-
-
Jiangsu
-
Nanjing、Jiangsu、中国、210008
- 招聘中
- Nanjing Drum Tower Hospital
-
接触:
- Yudong Qiu, Doctor
- 电话号码:13951806490
- 邮箱:yudongqiu510@163.com
-
Nanjing、Jiangsu、中国、210009
- 招聘中
- Zhongda Hospital Southeast University
-
接触:
- CaiLian Wang, Doctor
- 电话号码:13851756378
- 邮箱:wangcailian65@hotmail.com
-
Nanjing、Jiangsu、中国、210000
- 尚未招聘
- Jiangsu Provincial Cancer Hospital
-
接触:
- Yuanhua Liu, Doctor
- 电话号码:13305180356
- 邮箱:yuanhualiu02@hotmail.com
-
-
Jiangxi
-
Nanchang、Jiangxi、中国、330000
- 尚未招聘
- Jiangxi Provincal People's Hospital
-
接触:
- Weirong Yao, Doctor
- 电话号码:13907002901
- 邮箱:13907002901@126.com
-
-
Jilin
-
Changchun、Jilin、中国、130021
- 尚未招聘
- Jilin Cancer Hospital
-
接触:
- Hongxia Cui, Master
- 电话号码:13504436090
- 邮箱:2503074283@qq.com
-
Changchun、Jilin、中国、130021
- 尚未招聘
- The first hospital of Jilin University
-
接触:
- Tingting Liang, Doctor
- 电话号码:15804303776
- 邮箱:liangting2006@163.com
-
-
Liaoning
-
Shenyang、Liaoning、中国、110000
- 招聘中
- Liaoning Cancer Hospital & Institute
-
接触:
- Jingdong Zhang, Doctor
- 电话号码:18040007878
- 邮箱:13804027878@163.com
-
-
Shaanxi
-
Xi'an、Shaanxi、中国、710000
- 尚未招聘
- The First Affiliated Hospital of Xi'an Jiaotong University Medical College
-
接触:
- Aili Suo, Doctor
- 电话号码:18991232561
- 邮箱:Ailisuo@mail.xjtu.edu.cn
-
-
Shanghai Municipality
-
Shanghai、Shanghai Municipality、中国、200127
- 招聘中
- Renji Hospital, Shanghai Jiao Tong University School of Medicine
-
接触:
- XiuYing Xiao, Doctor
- 电话号码:13564579313
- 邮箱:xiaoxiuying2002@163.com
-
-
Shanxi
-
Xi’an、Shanxi、中国、710000
- 尚未招聘
- The Second Affiliated Hospital of Air Force Medical University
-
接触:
- Haichuan Su, Doctor
- 电话号码:18629190366
- 邮箱:cntdgcp@163.com
-
Xi’an、Shanxi、中国、710000
- 尚未招聘
- The First Affiliated Hospital of Air Force Medical University
-
接触:
- Yongzhan Nie, Doctor
- 电话号码:15091520001
- 邮箱:nieyongzhan@qq.com
-
-
Tianjin Municipality
-
Tianjin、Tianjin Municipality、中国、300202
- 招聘中
- Tianjin Medical University Cancer Institute & Hospital
-
接触:
- Zhanyu Pan, Master
- 电话号码:18622221256
- 邮箱:tjpanzy@126.com
-
Tianjin、Tianjin Municipality、中国、300121
- 尚未招聘
- Tianjin Union Medical Center
-
接触:
- Mingqing Zhang, Doctor
- 电话号码:15122875158
- 邮箱:zmq1003@163.com
-
-
Xinjiang
-
Ürümqi、Xinjiang、中国、830054
- 尚未招聘
- Xinjiang Medical University Affiliated Tumor Hospital
-
接触:
- YanLi Qu, Master
- 电话号码:18160627963
- 邮箱:quyanli73@163.com
-
-
Zhejiang
-
Lishui、Zhejiang、中国、323000
- 招聘中
- Lishui Municipal Central Hospital
-
接触:
- Yanru Xie, Master
- 电话号码:13567615770
- 邮箱:43437677@qq.com
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Participants voluntarily participate in this study, sign the informed consent form, and have good compliance
- Age: 18-75 years (including the boundary when signing the informed consent form)
- Eastern Cooperative Oncology Group (ECOG) score: 0-1
- Expected survival of more than 3 months
- Unresectable locally advanced or metastatic colorectal cancer diagnosed by histopathology/cytology
- HER2-Abnormally Expressed tested
- Presence of at least one measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria
- Participants should agree to use contraception during the study and for 6 months after the end
Exclusion Criteria:
- Participants with previously confirmed Microsatellite Instability Microsatellite Instability-High Deficient Mismatch Repair (MSI-H/dMMR)
- Presence of conditions affecting intravenous, venous blood sampling, or multiple factors affecting oral medications
- Active inflammatory bowel disease within 28 days prior to first dose
- Other malignancies within 5 years prior to the first dose or currently suffering from other malignancies
- Unresolved toxicity greater than CTCAE Grade 1 due to any prior therapy
- Major surgical treatment, significant traumatic injury within 28 days prior to the first dose or anticipation of major surgery during study treatment
- Had wounds or fractures that had not been healed for a long time
- Cerebrovascular accident, deep venous thrombosis and pulmonary embolism within 6 months prior to the first dose
- Patients with a history of psychotropic substance abuse who cannot quit or have mental disorders
- Participants with any severe and/or uncontrolled disease
- Known tumor-related carcinomatous meningitis with symptoms of brain metastases or symptom control for less than 4 weeks
- Patients with imaging suggestive of tumor invasion of major blood vessels or fatal massive hemorrhage due to tumor rupture or invasion of major blood vessels judged by the investigator to be very likely to occur during the study
- Failure to control serous effusions requiring repeated drainage
- Local radiotherapy or 4. Bone marrow irradiation > 30% for bone metastasis before the first medication
- Known tumor-related spinal cord compression, weight-bearing bone pathological fracture, extensive bone metastasis, or uncontrollable tumor bone metastasis-related pain
- Patients who have received chemotherapy, targeted therapy, immunotherapy or other systemic anti-tumor drug therapy before the first medication;
- Received Chinese patent medicine treatment with anti-tumor indications in the package insert of National Medical Products Administration (NMPA) approved drugs before study treatment
- History of live attenuated vaccination before the first dose or planned live attenuated vaccination during the study;
- Previous history of severe allergy of unknown origin
- According to the investigator's judgment, there are concomitant diseases that seriously endanger the participants' safety or affect the completion of the study, or the participant is considered unsuitable for other reasons
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:TQB2930 injection +chemotherapy + Bevacizumab injection
|
TQB2930 enhances the binding to HER2 protein on the surface of tumor cells and increases HER2 internalization by simultaneously targeting ECD2 and ECD4, two non-overlapping epitopes of HER2 protein, which in turn more effectively down-regulates HER2 protein on the surface of tumor cells and dually blocks HER2 signaling. Oxaliplatin can block DNA replication and transcription and induce tumor cell apoptosis. Irinotecan hydrochloride injection inhibits topoisomerase-I via its active metabolite SN-38, prevents religation of DNA single-strand breaks, causes irreversible DNA double-strand damage and induces tumor cell apoptosis. Capecitabine inhibits thymidylate synthase (TS) and interferes with DNA synthesis. Bevacizumab blocks VEGF binding to receptors and inhibits tumor angiogenesis. |
|
有源比较器:TQB2930 injection +chemotherapy
|
TQB2930 enhances the binding to HER2 protein on the surface of tumor cells and increases HER2 internalization by simultaneously targeting ECD2 and ECD4, two non-overlapping epitopes of HER2 protein, which in turn more effectively down-regulates HER2 protein on the surface of tumor cells and dually blocks HER2 signaling. Oxaliplatin can block DNA replication and transcription and induce tumor cell apoptosis. Irinotecan hydrochloride injection inhibits topoisomerase-I via its active metabolite SN-38, prevents religation of DNA single-strand breaks, causes irreversible DNA double-strand damage and induces tumor cell apoptosis. Capecitabine inhibits thymidylate synthase (TS) and interferes with DNA synthesis. |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Recommended Phase 2 Dose
大体时间:Baseline up to 21 days
|
It refers to the safe and effective dose range that can be used for phase II study determined through phase I clinical trial. |
Baseline up to 21 days
|
|
Adverse event (AE)
大体时间:From the participants signing of the informed consent form to 28 days after the last dose or the start of new anti-tumor therapy (whichever occurs first)
|
Incidence and severity of adverse events. |
From the participants signing of the informed consent form to 28 days after the last dose or the start of new anti-tumor therapy (whichever occurs first)
|
|
Objective Response Rate
大体时间:Baseline up to 24 months
|
The proportion of participants achieving complete response and partial response among the total evaluable cases. |
Baseline up to 24 months
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Half-life
大体时间:Baseline up to 24 months
|
The time it takes for the concentration of a drug in the body (usually the plasma concentration) to decrease to half of its initial value. |
Baseline up to 24 months
|
|
Plasma concentration-time profiles
大体时间:Baseline up to 24 months
|
Total area covered under the curve plotted with time as X-axis and plasma concentration as Y-axis. |
Baseline up to 24 months
|
|
Apparent clearance
大体时间:Baseline up to 24 months
|
The rate at which the drug is cleared from the body. |
Baseline up to 24 months
|
|
Apparent terminal volume of distribution
大体时间:Baseline up to 24 months
|
Describe the drug distribution in the body. |
Baseline up to 24 months
|
|
Trough plasma concentration
大体时间:Baseline up to 24 months
|
Minimum plasma drug concentration level at the end of the dosing interval (before the next dosing). |
Baseline up to 24 months
|
|
Disease Control Rate
大体时间:Baseline up to 24 months
|
The percentage of participants with a complete response, partial response, or stable disease as determined by RECIST 1.1. |
Baseline up to 24 months
|
|
Duration Of Response
大体时间:Baseline up to 24 months
|
The time from the first assessment of the tumor as a complete response or partial response to the first occurrence of disease progression or death from any cause. |
Baseline up to 24 months
|
|
Progression Free Survival
大体时间:Baseline up to 24 months
|
Progression Free Survival (PFS) is defined as the length of time from the start of treatment until the disease progresses or the patient dies from any cause. |
Baseline up to 24 months
|
|
Overall Survival
大体时间:Baseline up to 24 months
|
The time from the start of initial treatment to death from any cause. |
Baseline up to 24 months
|
|
Anti-Drug Antibodies (ADA) incidence
大体时间:Baseline up to 24 months
|
Proportion of anti-drug antibody produced in the population of patients using the drug. |
Baseline up to 24 months
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.